Post-chemotherapy rheumatism is a rare syndrome characterised by polyarthralgia that develops following a period of 1 to 4 months of various forms of chemotherapy for cancer treatment. There is very little representation of post-chemotherapy rheumatism (PCR) in literature. Here we report the case of a 21 years old girl with Hodgkin lymphoma who was not treated with cyclophosphamide, the drug considered as an etiological factor in PCR. Rather, we suggest the possibility of a transitory dysfunction in immunological tolerance mechanisms.
post-chemotherapy rheumatism; Hodgkin's lymphoma; immunological tolerance
